Neuroblastoma Global Market Report 2025

Neuroblastoma is a type of cancer that predominantly affects children, originating from immature nerve cells called neuroblasts. This cancer often develops in the adrenal glands, which sit atop the kidneys, but it can also occur in other regions of the abdomen, chest, neck, or pelvis. Symptoms associated with neuroblastoma may include abdominal pain, swelling, fatigue, and in some cases, bone pain or the presence of lumps.

The primary product types for treating neuroblastoma include tablets, vaccines, and others. Tablets are solid oral dosages containing active ingredients, binders, and fillers, used in the treatment of neuroblastoma to administer chemotherapy or targeted therapy drugs. Treatment options for neuroblastoma include chemotherapy, immunotherapy, and other approaches, which are distributed through various channels, both online and offline. These treatments are typically used in hospitals and clinics.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The neuroblastoma market research report is one of a series of new reports from The Business Research Company that provides neuroblastoma market statistics including the neuroblastoma industry global market size regional shares competitors with the neuroblastoma market share detailed neuroblastoma market segments market trends and opportunities and any further data you may need to thrive in the neuroblastoma industry. This neuroblastoma market research report delivers a complete perspective of everything you need with an in-depth analysis of the current and future scenarios of the industry.

The neuroblastoma market size has grown strongly in recent years. It will grow from $2.97 billion in 2024 to $3.14 billion in 2025 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to increase in neuroblastoma prevalence, increase in research and development for pediatric neuroblastoma treatments, increase in the incidence of childhood cancer and growing funding and support from government.

The neuroblastoma market size is expected to see strong growth in the next few years. It will grow to $3.91 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to increasing government funding, increasing incidence of the disease, growing focus on early detection, increasing prevalence of genetic mutations, and increasing understanding and research advancements. Major trends in the forecast period include development of drugs targeting specific molecular pathways, innovations in non-invasive imaging technologies, advances in gene-editing technologies, increasing focus on personalized treatment, the development of radiolabeled compounds.

The forecast of 5.6% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper pediatric oncology by increasing the cost of GD2-targeting immunotherapies and MetaIodoBenzylGuanidine therapy (MIBG therapy) systems imported from the Netherlands and Belgium, thereby limiting treatment options for childhood cancers and elevating pediatric Intensive Care Unit(ICU) costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growth of the neuroblastoma market is expected to be driven by the rising incidence of childhood cancer. Childhood cancer refers to a group of cancers that primarily affect children and adolescents, often targeting organs such as the brain, blood, and bones, and requiring specialized treatment methods. This increase in childhood cancer cases can be attributed to several factors, including advancements in diagnostic techniques, greater awareness, environmental exposures, genetic factors, and progress in medical research. Neuroblastoma treatments offer targeted therapies for childhood cancer, allowing for early intervention that reduces the risk of recurrence and improves the prognosis for young patients. For example, in May 2024, the American Cancer Society, a US-based professional organization, projected that around 9,620 children under the age of 15 in the United States would be diagnosed with cancer in 2024, up from 5,290 cases in 2023. As a result, the rising incidence of childhood cancer is a key factor driving the growth of the neuroblastoma market.

Leading companies in the neuroblastoma market are concentrating on developing innovative therapeutic interventions, such as humanized anti-GD2 monoclonal antibodies, to more effectively and safely target cancer cells. These antibodies are engineered to specifically target the GD2 molecule on cancer cells while minimizing immune rejection by incorporating human components. For example, in August 2023, Renaissance Pharma Ltd., a UK-based clinical-stage pharmaceutical company, announced that it had in-licensed Hu14.18K322A (Hu14.18) from St. Jude Children's Research Hospital. This antibody is designed for the treatment of newly diagnosed high-risk neuroblastoma, a rare and aggressive childhood cancer. According to the agreement, Renaissance has obtained exclusive rights to develop, manufacture, and commercialize Hu14.18 in key global markets, including the United States, Canada, Europe, China, Japan, and Turkey.

In September 2024, Ligand Pharmaceuticals Inc., a US-based biopharmaceutical company, completed the acquisition of Apeiron Biologics AG for $100 million. Through this acquisition, Ligand gains royalty rights to Qarziba and aims to enhance its commercial royalty portfolio by adding a high-value immunotherapy for high-risk neuroblastoma. This move is expected to drive growth by generating long-term, predictable revenue from a diverse range of key products. Apeiron Biologics AG, based in Austria, is a biotech company specializing in the development of immunotherapies for neuroblastoma.

Major players in the neuroblastoma market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Sartorius AG, Recordati S.p.A, United Therapeutics Corporation, BeiGene Ltd., MacroGenics Inc., Y-mAbs Therapeutics Inc., RedHill Biopharma Ltd., Clarity Pharmaceuticals Ltd., EUSA Pharma (UK) Ltd., US WorldMeds LLC, Healio Inc., Ascentage Pharma, Laboratorio Elea Phoenix S.A, Curis Inc., PersonGen BioTherapeutics (Suzhou) Co. Ltd., Essential Pharma S.A, Cellectar Biosciences Inc., Provectus Biopharmaceuticals Inc.

North America was the largest region in the neuroblastoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neuroblastoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Neuroblastoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neuroblastoma market consists of revenues earned by entities by providing services such as diagnosis and imaging, oncology treatment, and stem cell transplants. The market value includes the value of related goods sold by the service provider or included within the service offering. The neuroblastoma market also consists of sales of radiopharmaceuticals, monoclonal antibodies, and diagnostic tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods..

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neuroblastoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neuroblastoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neuroblastoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The neuroblastoma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Types: Tablets; Vaccines; Other Product Types
• 2) By Treatment Type: Chemotherapy; Immunotherapy; Other Treatment Types
• 3) By Distribution Channel: Online; Offline
• 4) By End-User: Hospitals; Clinics
• Subsegments:
• 1) By Tablets: Oral Chemotherapy Tablets; Targeted Therapy Tablets
• 2) By Vaccines: Immunotherapy Vaccines; Therapeutic Vaccines
• 3) By Other Product Types: Injectable Drugs; Monoclonal Antibodies; Cell Therapy Products
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Eli Lilly and Company; Sartorius AG; Recordati S.p.A; United Therapeutics Corporation; BeiGene Ltd.; MacroGenics Inc.; Y-mAbs Therapeutics Inc.; RedHill Biopharma Ltd.; Clarity Pharmaceuticals Ltd.; EUSA Pharma (UK) Ltd.; US WorldMeds LLC; Healio Inc.; Ascentage Pharma; Laboratorio Elea Phoenix S.A; Curis Inc.; PersonGen BioTherapeutics (Suzhou) Co. Ltd.; Essential Pharma S.A; Cellectar Biosciences Inc.; Provectus Biopharmaceuticals Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.